摘要
Due mainly to a late stage at diagnosis and lack of effective treatment modalities,pancreatic cancer(PC)is a highly lethal malignancy with an overall 5-year survival rate of only 12%.1 Separating patients into those diagnosed with latestage disease with distant metastases and those diagnosed with localized tumors reveals a striking difference of 3%vs.44%5-year survival rates,respectively.Increasing the fraction of patients detected at an early stage,when PC is most likely to be curable,could therefore be of a major benefit.
基金
supported by the Intramural Research Program(IRP)of the Division of Cancer Epidemiology and Genetics(DCEG)
National Cancer Institute(NCI)
US National Institutes of Health(NIH).